Date: 2013-08-17
Type of information: Grant
Company: Bionor Pharma (Norway)
Investors: the Research Council of Norway (Norway)
Amount: NOK 7.7 million (€ 0.97 million)
Funding type: grant
Planned used: This grant will be used for partial funding of the Vacc-HIV project. Vacc-HIV combines Bionor Pharma’s two therapeutic HIV vaccine candidates Vacc-4x and Vacc-C5. Vacc-HIV aims to induce immune cells that can kill virus infected cells (Vacc-4x) and generate antibodies to reduce hyper immune activation caused by HIV (Vacc-C5). The Vacc-HIV studies funded by the grant from GLOBVAC will be carried out in collaboration with St. George’s University, London, St Georges Healthcare NHS Trust and the University of Lausanne in Switzerland.
Others: * On August 17, 2013, Bionor Pharma announced that the earlier announced grant from GLOBVAC for partial funding of the Vacc-HIV project (please see release published 21 June) has been confirmed and will be funded with NOK 7.7 million (€ 0.97 million). Support from GLOBVAC help to advance HIV therapeutic vaccine research towards a functional cure * On June 21, 2013, Bionor Pharma announced that the Research Council of Norway through its GLOBVAC program (for Global Health and Vaccine Research) has awarded Bionor Pharma partial funding for preclinical studies and a phase I/II clinical trial on Vacc-HIV, a combination of Vacc-4x and Vacc-C5. The grant is titled “Vacc-HIV: A novel therapeutic vaccine combination for HIV infection.”
Therapeutic area: Infectious diseases
